DT05 Rec'd PCT/PTO 0:2 DEC 2000

·	•	·		a DEO CUR					
FORM F	PTO-139	0 (Modified) U.S. DEPARTMENT OF COM	IMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER					
(ICEV. I	TF	RANSMITTAL LETTER	TO THE UNITED STATES	PU4828USW					
		DESIGNATED/ELECTI	ED OFFICE (DO/EO/US)	U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR					
		CONCERNING A FILIN	IG UNDER 35 U.S.C. 371	10/516577					
INTE		IONAL APPLICATION NO. PCT/US03/17347	INTERNATIONAL FILING DATE June 3, 2003	PRIORITY DATE CLAIMED June 4, 2002					
TITLE	OF IN	VENTION							
Phar	mace	eutical Compositions Compri	sing Abacavir and Lamivudine						
			•						
		Γ(S) FOR DO/EO/US							
CUR	RIE,	, Robin; GOODSON, Gary, V	Vayne						
Appli	cant h	erewith submits to the United Sta	tes Designated/Elected Office (DO/EO/US) th	e following items and other information:					
1.	×	This is a FIRST submission of i	tems concerning a filing under 35 U.S.C. 371.						
2.			UENT submission of items concerning a filing						
3.	\boxtimes	_		. 371(f)). The submission must include items (5),					
		(6), (9) and (24) indicated below		、 ,					
4.		The US has been elected by the	expiration of 19 months from the priority date	(Article 31).					
5.	\boxtimes	••	ication as filed (35 U.S.C. 371 (c) (2))						
		· · ·	ired only if not communicated by the Internat	tional Bureau).					
			d by the International Bureau.						
			pplication was filed in the United States Recei						
6.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).							
		a. is attached hereto.		•					
			omitted under 35 U.S.C. 154(d)(4).						
7.	\boxtimes		International Application under PCT Article						
		·	uired only if not communicated by the Interna	itional Bureau).					
			ed by the International Bureau.	NOT and					
			owever, the time limit for making such amendr	ments has NOT expired.					
	_	d. A have not been made and		rticle 10 (35 U.S.C. 371(c)(3))					
8. 9.		An english language translation An oath or declaration of the inv	of the amendments to the claims under PCT A enter(s) $(35 \text{ LLS C}, 371 \text{ (c)}(4))$	THICLE 19 (33 O.S.C. 371(C)(3)).					
10.		An English language translation	of the annexes to the International Preliminary	Examination Report under PCT					
	EZ1	Article 36 (35 U.S.C. 3/1 (c)(5))							
11.	⊠ ⊠	A copy of the International Search	minary Examination Report (PCT/IPEA/409).						
12.									
		3 to 20 below concern documen							
13.	⊠ .		ement under 37 CFR 1.97 and 1.98. ording. A separate cover sheet in compliance	with 37 CEP 2.38 and 3.31 is included					
14.				with 57 CFR 5.28 and 5.51 is included.					
15. 16.		A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment.							
10. 17.		A substitute specification.							
18.		A change of power of attorney and/or address letter.							
19.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.							
20.		A second copy of the published international application under 35 U.S.C. 154(d)(4).							
21.		• •	nguage translation of the international applicat						
22.	\boxtimes		<u>′ 332063787 US</u>						
23.	\boxtimes	Other items or information:	•	. [1]					
		a) PCT Cover Page b) PCT Request							

PCTUS1/REV03

U.S. APPLIC					INTERNATIONALA			IO.			DOCKET NUMBER
	4	1/51	65		PCT/US	503/1734	17			PU48	28USW
24.	The foll	owing fees	are subr	nitted:.					CAL	CULATIONS	FTO USE ONLY
BASIC NAT	ΓΙΟΝΑΙ	L FEE (37	CFR 1.	492 (a) (1) - ((5)):						
interr	national	search fee (37 CFR	1 445(a)(2))	fee (37 CFR 1.482) no paid to USPTO by the EPO or JPO			\$1080.00			
USP?	ΓO but I	nternationa	l Search	Report prepa	CFR 1.482) not paid tared by the EPO or JPC)		\$920.00			
but ir	but international search fee (37 CFR 1.445(a)(2)) paid to USPTO							\$770.00			
out an elamb and not battory provided and the control of the contr							\$730.00				
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)							\$100.00				
										\$920.00	
months from	the earl	liest claimed	d priorit	y date (37 Cl	ration later than FR 1.492 (e)).	20	·	□ 30	ļ	\$0.00	
CLAIMS		NU	MBER		NUMBER EXT	RA	<u> </u>	RATE		672.00	
Total claims			24	- 20 =	4		х	\$18.00		\$72.00	
Independent			5	- 3 =	2		х	\$86.00		\$172.00	
Multiple De	pendent	Claims (ch	eck if a	pplicable).	A DOVE CAT C	TIT AT		NS =		\$0.00 \$1,164.00	
					ABOVE CALC			113 =		\$1,104.00	
	ant clain d by 1/2.		ity statu	is. See 3 / CFI	R 1.27. The fees indica		e are			\$0.00	
						SUB'	TO	$\Gamma AL =$		\$1,164.00	
Processing for months from	Processing fee of \$130.00 for furnishing the English translation later than										
					TOTAL NAT	IONAI	LF	EE =		\$1,164.00	
Fee for recor	Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).										
TOTAL FEES ENCLOSED =								\$1,164.00			
							unt to be: efunded	\$			
										charged	\$
a. 🗆 b. 🛛	Pleas		y Depos	sit Account N		in the am	ount	of \$1,1			ne above fees.
с. 🛚	c. The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>07-1392</u>										
d. 🗖	d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.										
NOTE: Wh 1.137(a) or (ere an : (b)) mus	appropriat	e time li nd grai	imit under 37 nted to restor	CFR 1.494 or 1.495 the application to p	has not b	een i	met, a petitio	on to r	evive (37 CFR	
SEND ALL	CODDE	CDONIDEN	ICE TO					. /		25/	
SEND ALL	CORKE	SFONDEN	CE 10				=	Turen		Trus	<u> </u>
	SIGNATURE										
00047						NAME 39,337					
23347				ALAWA (DEP							
		_	-				RI	EGISTRATIO	, א אר	MBEK	,
								il econ	Sar	2 20r	74
							Ď	ATE		/	•

10/516577

CERTIFICATE OF I		ESS MAIL" (37 CFR 1.10)05 Rec'e	PU4828USW
Serial No. To Be Assigned	Filing Date Concurrently Herewith		Group Art Unit
vention: Pharmaceuti	cal Compositions Comprisin	ng Abacavir and Lamivudine	
I hereby certify that the	e following correspondence	:	
National Phase Applica	ation with accompanying pa	pers	
		ify type of correspondence)	
is being deposited wit	th the United States Postal	Service "Express Mail Post Office to A	ddressee" service under 37
		sioner for Patents, P.O. Box 1450, Alex	Carlotta, VA 22010-1400 OF
	(Date)		
	(Duie)	Valerie L. Phil	lips
		(Typed or Printed Name of Person Ma.	iling Correspondence)
		Vallere Z Shi	lly
		EV332063	Parresnondence)
		("Express Mail" Mailing La	- L
	•		